References
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57.
- Gray JH, Mangravite LM, Owen RP et al. Functional and genetic diversity in the concentrative nucleoside trans-porter, CNT1, in human populations. Mol Pharmacol 2004; 65: 512.
- Fitzsimmons SA, Workman P, Greyer M, Paull K, Camalier R, Lewis AD. Reductase enzyme expression across the National Cancer Institute tumor cell line panel: correlation with sensitivity to mitomycin C and E09. J Natl Cancer Inst 1996; 88 (5): 259–69.
- Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335.
- Mayer RJ. Two steps forward in the treatment of col-orectal cancer. N Engl J Med. 2004; 350: 2406.
- Elkin M, Reich R, Nagler A et al. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J. 2000; 14: 2477.
- Dancey J, Sausville EA Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Disc 2003; 2: 296.
- Adams J, Kauffman M Development of the proteosome inhibitor velcade (Bortezomib). Cancer Invest 2004; 22: 304.